End Stage Renal Disease disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: END086 MIFTS: 50	End Stage Renal Disease Categories: Nephrological diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for End Stage Renal Disease

MalaCards integrated aliases for End Stage Renal Disease:

Name: End Stage Renal Disease ¹¹ ¹⁴ ⁷⁵

Chronic Kidney Disease Stage 5 ⁷¹

End-Stage Kidney Disease ¹¹

End Stage Renal Failure ¹¹

Kidney Failure, Chronic ⁷¹

Classifications:

MalaCards categories:
Anatomical: Nephrological diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹¹ DOID:783

ICD9CM ³⁴ 585.6

UMLS ⁷¹ C0022661 C2316810

Sources

Summaries for End Stage Renal Disease

Disease Ontology: ¹¹ A chronic kidney disease is characterized by non-functioning kidneys, as the final stage in chronic kidney disease.

MalaCards based summary: End Stage Renal Disease, also known as chronic kidney disease stage 5, is related to chronic kidney disease and microvascular complications of diabetes 5, and has symptoms including cloudy (hemodialysis) (peritoneal) dialysis effluent An important gene associated with End Stage Renal Disease is ACE (Angiotensin I Converting Enzyme), and among its related pathways/superpathways are ACE Inhibitor Pathway, Pharmacodynamics and Primary focal segmental glomerulosclerosis (FSGS). The drugs Digoxin and Peginterferon alfa-2b have been mentioned in the context of this disorder. Affiliated tissues include kidney, bone marrow and bone, and related phenotypes are homeostasis/metabolism and cardiovascular system

Sources

Related Diseases for End Stage Renal Disease

Diseases related to End Stage Renal Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1470)

#	Related Disease	Score	Top Affiliating Genes
1	chronic kidney disease	32.9	THBD RNLS PON1 MYH9 INVS EPO
2	microvascular complications of diabetes 5	32.8	VEGFA SOD2 PON1 ACE
3	focal segmental glomerulosclerosis 5	32.7	CD2AP APOL1 ACTN4
4	autosomal recessive alport syndrome	32.7	MYH9 CD2AP ACTN4 ACE
5	alport syndrome	32.6	MYH9 CFH CD2AP APOL1 ACTN4 ACE
6	focal segmental glomerulosclerosis 2	32.6	CD2AP ACTN4
7	type 1 diabetes mellitus	32.5	VEGFA PVT1 PON1 ACE
8	focal segmental glomerulosclerosis 6	32.4	CD2AP ACTN4
9	nephronophthisis 7	32.4	NEK8 INVS
10	infantile nephronophthisis	32.4	NEK8 INVS
11	nephronophthisis 16	32.4	NEK8 INVS
12	uremia	32.3	PON1 EPO ACE
13	nephronophthisis 9	32.2	NEK8 INVS
14	glomerulonephritis	32.2	MYH9 IL1RN CFH APOL1 ACTN4 ACE
15	peripheral vascular disease	32.0	VEGFA THBD EPO ACE
16	deficiency anemia	32.0	VEGFA SOD2 PON1 HFE EPO CFH
17	polycystic kidney disease	31.9	VEGFA NEK8 INVS EPO ACE
18	kidney disease	31.9	VEGFA THBD RNLS PON1 NEK8 MYH9
19	autosomal dominant polycystic kidney disease	31.8	NEK8 INVS EPO APOL1 ACE
20	diabetes mellitus	31.7	VEGFA THBD SOD2 PVT1 PON1 IL1RN
21	sleep apnea	31.7	VEGFA EPO ACE
22	iga glomerulonephritis	31.7	CFH CD2AP ACE
23	focal segmental glomerulosclerosis	31.7	PON1 MYH9 CD2AP APOL1 ACTN4 ACE
24	type 2 diabetes mellitus	31.6	VEGFA THBD SOD2 PVT1 PON1 IL1RN
25	neuropathy	31.6	VEGFA SOD2 EPO ACE
26	cystic kidney disease	31.6	NEK8 INVS EPO ACE
27	pulmonary edema	31.6	IL1RN EPO ACE
28	interstitial nephritis	31.6	INVS APOL1 ACE
29	acute myocardial infarction	31.5	VEGFA THBD PON1 HFE ACE
30	nephrotic syndrome	31.5	VEGFA PON1 MYH9 EPO CD2AP APOL1
31	stroke, ischemic	31.5	VEGFA THBD SOD2 PON1 ACE
32	pre-eclampsia	31.4	VEGFA THBD PON1 BDKRB2 ACE
33	hypertension, essential	31.4	VEGFA THBD SOD2 RNLS PON1 MYH9
34	lipoprotein quantitative trait locus	31.4	VEGFA THBD PON1 IL1RN ACE
35	ischemia	31.3	VEGFA SOD2 PON1 IL1RN EPO ACE
36	renal artery disease	31.3	EPO APOL1 ACE
37	blood platelet disease	31.3	VEGFA THBD MYH9 EPO CFH
38	chronic pyelonephritis	31.3	EPO ACE
39	heart disease	31.3	VEGFA THBD SOD2 PON1 IL1RN HFE
40	eclampsia	31.2	VEGFA THBD ACE
41	antiphospholipid syndrome	31.2	THBD PON1 CFH
42	myocardial infarction	31.2	VEGFA THBD SOD2 PON1 IL1RN HFE
43	membranoproliferative glomerulonephritis	31.1	THBD CFH APOL1 ACE
44	lipoid nephrosis	31.1	CD2AP APOL1 ACTN4
45	thrombocytopenia	31.1	VEGFA THBD MYH9 IL1RN EPO CFH
46	hypertensive encephalopathy	31.1	VEGFA EPO ACE
47	angioedema	31.1	BDKRB2 BDKRB1 ACE
48	hypertensive retinopathy	31.0	VEGFA CFH ACE
49	lung disease	31.0	VEGFA SOD2 IL1RN ACE
50	kidney papillary necrosis	31.0	APOL1 ACE

Graphical network of the top 20 diseases related to End Stage Renal Disease:

Sources

Symptoms & Phenotypes for End Stage Renal Disease

UMLS symptoms related to End Stage Renal Disease:

cloudy (hemodialysis) (peritoneal) dialysis effluent

MGI Mouse Phenotypes related to End Stage Renal Disease:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.3	ACE ACTN4 BDKRB1 BDKRB2 CD2AP CFH
2	cardiovascular system	MP:0005385	10.19	ACE ACTN4 APOL1 BDKRB1 BDKRB2 CD2AP
3	renal/urinary system	MP:0005367	10.17	ACE ACTN4 BDKRB2 CD2AP CFH INVS
4	cellular	MP:0005384	10.1	ACE ACTN4 BDKRB2 EPO HFE IL1RN
5	immune system	MP:0005387	10.03	ACE ACTN4 BDKRB1 BDKRB2 CD2AP CFH
6	liver/biliary system	MP:0005370	10.01	ACE ACTN4 EPO HFE INVS SOD2
7	hematopoietic system	MP:0005397	9.86	ACE ACTN4 BDKRB1 BDKRB2 CD2AP CFH
8	mortality/aging	MP:0010768	9.47	ACE ACTN4 BDKRB2 CD2AP CFH EPO

Sources

Drugs & Therapeutics for End Stage Renal Disease

Drugs for End Stage Renal Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 554)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Digoxin

Approved

Phase 4

20830-75-5

3062 2724385 30322

Peginterferon alfa-2b

Approved

Phase 4

215647-85-1, 99210-65-8

Chlorhexidine

Approved, Vet_approved, Withdrawn

Phase 4

55-56-1

2713 9552079

Candesartan cilexetil

Approved

Phase 4

145040-37-5

Irbesartan

Approved, Investigational

Phase 4

138402-11-6

3749

Oxycodone

Approved, Illicit, Investigational

Phase 4

76-42-6

5284603

Ursodeoxycholic acid

Approved, Investigational

Phase 4

128-13-2

31401

Capsaicin

Approved

Phase 4

404-86-4

1548943

Valsartan

Approved, Investigational

Phase 4

137862-53-4

60846

Enalaprilat

Approved

Phase 4

76420-72-9

6917719 5462501

Enalapril

Approved, Vet_approved

Phase 4

75847-73-3

40466924 5388962 5362032

Alprostadil

Approved, Investigational

Phase 4

745-65-3

5280723

Nadroparin

Approved, Investigational

Phase 4

Lactitol

Approved, Investigational

Phase 4

585-86-4

157355

Olmesartan

Approved, Investigational

Phase 4

144689-63-4, 144689-24-7

158781 130881

Rivaroxaban

Approved

Phase 4

366789-02-8

9875401

Allopurinol

Approved

Phase 4

315-30-0

2094 135401907

Darbepoetin alfa

Approved, Investigational

Phase 4

209810-58-2

Everolimus

Approved

Phase 4

159351-69-6

70789204 6442177

Amlodipine

Approved

Phase 4

88150-42-9

2162

Bisoprolol

Approved

Phase 4

66722-44-9

2405

Pioglitazone

Approved, Investigational

Phase 4

111025-46-8

4829

Peginterferon alfa-2a

Approved, Investigational

Phase 4

198153-51-4

Ribavirin

Approved

Phase 4

36791-04-5

37542

Alemtuzumab

Approved, Investigational

Phase 4

216503-57-0

Liraglutide

Approved

Phase 4

204656-20-2

44147092 16134956

Iron

Approved

Phase 4

7439-89-6

29936

Taurolidine

Approved, Investigational

Phase 4

19388-87-5

Ritonavir

Approved, Investigational

Phase 4

155213-67-5

392622

Argatroban

Approved, Investigational

Phase 4

74863-84-6

152951 92722

Colchicine

Approved

Phase 4

64-86-8

2833 6167

Levoleucovorin

Approved, Experimental, Investigational

Phase 4

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Prednisolone phosphate

Approved, Vet_approved

Phase 4

302-25-0

Prednisolone acetate

Approved, Vet_approved

Phase 4

52-21-1

Prednisolone

Approved, Vet_approved

Phase 4

50-24-8

4894 5755

Methylprednisolone hemisuccinate

Approved

Phase 4

2921-57-5

1875

Methylprednisolone

Approved, Vet_approved

Phase 4

83-43-2

4159 6741

Pentoxifylline

Approved, Investigational

Phase 4

6493-05-6

4740

Miconazole

Approved, Investigational, Vet_approved

Phase 4

22916-47-8

4189

Clotrimazole

Approved, Vet_approved

Phase 4

23593-75-1

2812

Sirolimus

Approved, Investigational

Phase 4

53123-88-9

5284616 6436030

Basiliximab

Approved, Investigational

Phase 4

179045-86-4

Pantoprazole

Approved

Phase 4

102625-70-7, 138786-67-1

4679

Thiopental

Approved, Vet_approved

Phase 4

76-75-5

3000715

Remifentanil

Approved

Phase 4

132875-61-7

60815

Desflurane

Approved

Phase 4

57041-67-5

42113

Mupirocin

Approved, Investigational, Vet_approved

Phase 4

12650-69-0

446596

Reviparin

Approved, Investigational

Phase 4

9041-08-1

Eplerenone

Approved

Phase 4

107724-20-9

443872

Rocuronium

Approved

Phase 4

119302-91-9, 143558-00-3

441290

Interventional clinical trials:

(show top 50) (show all 1848)

#	Name	Status	NCT ID	Phase	Drugs
1	Marinobufagenin as a Target for DIGIBIND in Hypertensive Patients With End-stage Renal Disease	Unknown status	NCT00852787	Phase 4	Digoxin immune fab;Placebo
2	A comParison on Platelet Resistance With Ticagrelor or Standard-Dose Clopidogrel Study Among SeVerE Chronic Kidney Disease/ End-Stage-Renal-Disease Patients With Recent Acute Coronary Syndrome.	Unknown status	NCT02459288	Phase 4	Clopidogrel first;Ticagrelor first
3	The Efficacy and Safety of Niacin on Hyperphosphatemia in End Stage Renal Disease Patients Undergoing Haemodialysis	Unknown status	NCT03163576	Phase 4	Niacin;Phosphate Binder
4	The Effect of Far Infrared (FIR) Therapy on Access Flow of Arteriovenous (AV) Fistula, Echocardiographic Parameters and Endothelial Function in Patients With End Stage Renal Disease	Unknown status	NCT01138254	Phase 4
5	A Comparative Study of Dexmedetomidine and Propofol As Sole Sedative Agent for Patients With End-Stage Renal Disease Undergoing Arteriovenous Fistula Surgery	Unknown status	NCT02447796	Phase 4	Propofol;Dexmedetomidine
6	Hypervolemia and Treatment Guided by Bioimpedance in End Stage Renal Disease Patients in Zonguldak (Prospective Study)	Unknown status	NCT01468363	Phase 4
7	The Effect of Ferric Citrate on Inflammation and Lipid Levels in Patients on Hemodialysis	Unknown status	NCT02661295	Phase 4	Ferric Citrate
8	Effects of On-Line Hemodiafiltration(HDF) on Endothelial Dysfunction in Chronic Hemodialysis Patients	Unknown status	NCT00532597	Phase 4
9	The Impact of Conventional Hemodialysis, High Flux Hemodialysis and Hemodiafiltration on Adiponectin, Vascular Function and Clinical Prognosis	Unknown status	NCT00155363	Phase 4
10	The Association Between Body Composition and Biomarkers in Hemodialysis Patients	Unknown status	NCT01103167	Phase 4
11	Bicarbonate vs Heparin Catheter Lock in Chronic Hemodialysis Patients	Unknown status	NCT04054128	Phase 4	Sodium Bicarbonate 7.5% Injection;Heparin Sodium, 1000 Units/mL Injectable Solution 1
12	Efficacy and Safety of Local Application of Chlorhexidine Gluconate Versus Mupirocin Ointment in the Prevention of Peritoneal Dialysis-Related Infection: A Double-Blind, Stratified Randomized Controlled Trial	Unknown status	NCT02547103	Phase 4
13	The Effects of Acetylcysteine on Alleviating Damage of Oxidative Stress in Hemodialysis Patients	Unknown status	NCT00247507	Phase 4	acetylcysteine
14	Upstream Use of Aliskiren in Hypertensive Haemodialysis Patients: Effects on Cardiovascular Outcomes	Unknown status	NCT01635387	Phase 4	aliskiren
15	Effect of Add-on Spironolactone to Losartan Versus Losartan Alone on Peritoneal Membrane Among Continuous Ambulatory Peritoneal Dialysis Patients: An Open-Label Randomized-Controlled Trial	Unknown status	NCT03953950	Phase 4	Spironolactone;Losartan
16	The Determinants of the Effectiveness of the Use of Furosemide in Patients on Dialysis	Unknown status	NCT01815892	Phase 4	Withdrawal of furosemide;furosemide administration
17	A Pilot Study to Treat Patients With Chronic HCV Genotype 1 and ESRD Receiving Hemodialysis and Naïve to Prior HCV Therapy With Peginterferon Alfa-2b, the Maximally Tolerated Ribavirin Dose and Boceprevir	Unknown status	NCT01731301	Phase 4	Ribavirin;Peginterferon;Boceprevir
18	Clinical Trial Simulation Using ODE/PDE Hemodialysis Model for Quantifying Oxycodone's Removal in End-Stage Kidney Disease	Unknown status	NCT02452437	Phase 4	Oxycodone
19	A Prospective Randomized, Double-Blind Parallel Group Trial To Assess The Efficacy And Safety Of Intravenous Dextrose 5% Solution Compare With Normal Saline (Standard Care) In Rinsing During Haemodialysis In Subjects With End Stage Renal Failure (ESRF) With Respect To Systolic Blood Pressure Control Over 3 Months Period.	Unknown status	NCT02590081	Phase 4	Dextrose 5%;normal saline
20	Effect of Ursodeoxycholic Acid on Peritoneal Function in Patients on Peritoneal Dialysis	Unknown status	NCT02338635	Phase 4	Ursodeoxycholic Acid
21	A Randomized Prospective Trial of N-acetyl Cystein in Patients With Peritoneal Dialysis	Unknown status	NCT01111422	Phase 4	N-acetylcysteine
22	The Role of Qutenza (Topical Capsaicin 8%) in Treating Neuropathic Pain From Critical Ischaemia in Patients With End-stage Renal Failure	Unknown status	NCT01704339	Phase 4	QUTENZA
23	Inspiratory Muscle Training in Patients With End Stage Renal Failure: a Randomized Controlled Trial	Unknown status	NCT01347775	Phase 4
24	Effects of Cholecalciferol on Osteoprotegerin Levels and Other Clinical Outcomes in Chronic Kidney Disease Patients on Peritoneal Dialysis: a Randomized Controlled Trial	Unknown status	NCT02598635	Phase 4	Cholecalciferol;Placebo
25	Randomized, Open Label, Controlled Clinical Trial of Egg Albumin-Based Protein Supplement Versus Renal Specific Oral Supplement in Hemodialysis Patients	Unknown status	NCT01981083	Phase 4
26	Interstitial Fibrosis in Protocol Biopsies of Renal Allografts: A Prospective, Randomised Trial of Sirolimus Versus Cyclosporine.(Fibrasic)	Unknown status	NCT00493194	Phase 4	sirolimus;cyclosporine;daclizumab
27	Open Randomized Phase IV Study on Intravenous Iron in Anemic Patients With Chronic Kidney Disease	Unknown status	NCT00204256	Phase 4	Iron sucrose
28	Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease: An Interventional and Methodological Study	Unknown status	NCT00235287	Phase 4	Candesartan and enalapril;candesartan and enalapril
29	The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease	Unknown status	NCT01157260	Phase 4	Kremezin
30	Hemocontrol's Effectiveness in a RAndomized Controlled Trial on the Reduction of Cardiovascular Long-term EventS	Unknown status	NCT01515878	Phase 4
31	Impact of a Mineralocorticoid Receptor Antagonist on Chronic Histological Changes in Renal Allograft	Unknown status	NCT01510795	Phase 4	spironolactone
32	Clinical Trial, Open, Parallel Groups , Value the Antiproteinuric Effects From Vitamin D Derivatives in Patient With Chronic Kidney Illness and the Lack of Vitamin D	Unknown status	NCT01442272	Phase 4	Hidroferol®;Paricalcitol: Zemplar®;Habitual medication
33	Renal Toxicity of Iodixanol and Iopromide in Patients With Renal Dysfunction-a Multicentre, Single Blind, Randomized Controlled, Prospective Trial	Unknown status	NCT01580046	Phase 4	iodixanol;iopromide
34	Phase 4 Study of Alprostadil Prevent Contrast Induced Nephropathy in Patients Receiving a Cardiac Catheterization	Unknown status	NCT01722513	Phase 4	Alprostadil ﹠control
35	Evaluation of Nail Fold Microcirculation and Interventional Therapy in Patients With Chronic Renal Failure	Unknown status	NCT03682952	Phase 4	Alprostadil Injection;Beraprost sodium tablets
36	Effect of Hydration With Sodium Bicarbonate for Long-Term Clinical Outcomes in Patients With Chronic Kidney Disease Undergoing an Emergent Coronary Procedure	Unknown status	NCT00716001	Phase 4	N-acetylcysteine
37	Low-molecular Heparin Infusion as Anticoagulation for Nocturnal Home Hemodialysis	Unknown status	NCT02957877	Phase 4	Nadroparin;Unfractionated heparin
38	NAC in Preventing CIN in CRF Patients Who Need Enhanced CT Scan in ED	Unknown status	NCT00501475	Phase 4	NAC Bicarbonate
39	Providing Intravenous Paricalcitol Treatment to the Sick and Poor Chronic Hemodialysis Patients With Severe Secondary Hyperparathyroidism Resistant to Existing Vitamin D Analogs	Unknown status	NCT03023748	Phase 4	Intravenous Paricalcitol
40	Immunosuppression in Renal Transplantation in The Elderly: Time to Rethink. - nEverOld Study	Unknown status	NCT01631058	Phase 4	Everolimus
41	Simvastatin Effect on Endothelium Dependent Venodilation in Chronic Renal Failure Patients Treated by Peritoneal Dialysis	Unknown status	NCT00291863	Phase 4	Simvastatin
42	Study on the Effect of Hyperuricaemia on Chronic Renal Disease and Intervention	Unknown status	NCT03425708	Phase 4	20mg Febuxostat;40mg Febuxostat
43	the Effect of Calcium Dobesilate on Non Dialysis Patients With Chronic Renal Failure	Unknown status	NCT03427944	Phase 4	Calcium Dobesilate group;Conventional Treatment group
44	Effects of an Exercise Program in Patients With Hypertensive Chronic Kidney Disease: a Randomized Clinical Trial	Unknown status	NCT01155128	Phase 4
45	Renoprotection by Combining Pentoxifylline and Angiotensin Blockade in Chronic Kidney Disease	Unknown status	NCT01377285	Phase 4	ARB;Pentoxifylline;Placebo (for Pentoxifylline)
46	Does ALlopurinol Regress lefT Ventricular Hypertrophy in End Stage REnal Disease: The ALTERED Study	Completed	NCT01951404	Phase 4	Allopurinol;Placebo (for allopurinol)
47	Erythropoietins in Management of Anemia of End Stage Renal Disease: A Prospective Study From Qatar.	Completed	NCT02049346	Phase 4	Epoetin alpha or beta (Epoetin group);Darbepoetin alfa;Methoxy polyethylene glycol-epoetin beta
48	A Multicenter, Randomized, Placebo-controlled, Double-blind Study on the Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease (ESRD) in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD)	Completed	NCT00414440	Phase 4	Placebo;Everolimus
49	Streptococcus Pneumoniae Colonization and Immunogenicity of 13-valent Conjugate Pneumococcal Vaccine in Patients 50 Years or Older With End Stage Renal Disease on Dialysis.	Completed	NCT01974817	Phase 4
50	Effect of Amlodipine Versus Bisoprolol on Hypertensive Patients With End-stage Renal Disease on Maintenance Hemodialysis.	Completed	NCT04085562	Phase 4	Bisoprolol Fumarate 5-10 mg;Amlodipine 5-10 mg

Search NIH Clinical Center for End Stage Renal Disease

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

Aluminum carbonate

basic aluminum carbonate gel

Bumetanide

calcium acetate

Calcium Carbonate

CALCIUM CARBONATE 1 g in 1 g ORAL POWDER

Calcium gluceptate

Cholecalciferol

Dihydrotachysterol

dihydroxyaluminum sodium carbonate

Ethacrynate Sodium

Ethacrynic Acid

Furosemide

magaldrate

Magnesium Hydroxide

MILK OF MAGNESIA

torsemide

Sources

Genetic Tests for End Stage Renal Disease

Sources

Anatomical Context for End Stage Renal Disease

Organs/tissues related to End Stage Renal Disease:

MalaCards : Kidney, Bone Marrow, Bone, Endothelial, Colon, Heart, Liver

Sources

Publications for End Stage Renal Disease

Articles related to End Stage Renal Disease:

(show top 50) (show all 40985)

#	Title	Authors	PMID	Year
1	Establishment of Reference Values for Non-HLA Antibodies in Patients With End-stage Renal Disease. ⁶²	Shin KH...Kim HH	36281519	2023
2	Prognostic Predictors of Mortality in Male Breast Cancer: Outcomes in an Urban Population. ⁶²	Sogunro OA...Son JD	36182676	2023
3	Paradigm shift in lifestyle modification for solitary kidney after donor nephrectomy. ⁶²	Tantisattamo E...Kalantar-Zadeh K	36444664	2023
4	The role of age on the risk relationship between prediabetes and major morbidities and mortality: Analysis of the Hong Kong diabetes surveillance database of 2 million Chinese adults. ⁶²	Zhang X...Luk AOY	36419741	2023
5	Clinical outcomes following discontinuation of renin-angiotensin-system inhibitors in patients with type 2 diabetes and advanced chronic kidney disease: A prospective cohort study. ⁶²	Yang A...Chow E	36457651	2023
6	Nicorandil protects podocytes via modulation of antioxidative capacity in acute puromycin aminonucleoside-induced nephrosis in rats. ⁶²	Yamanaka M...Shibata S	36454699	2022
7	Delayed gastric emptying in nondiabetic patients with end-stage kidney disease. ⁶²	Wang C...Zhao C	35188060	2022
8	Characteristics and outcomes among pregnant women with end-stage renal disease on hemodialysis. ⁶²	Lavie A...Abenhaim HA	34030571	2022
9	Acute kidney injury in critically ill patients with COVID-19: prevalence, risk factors and mortality in eastern Morocco. ⁶²	Ounci E...Housni B	36006607	2022
10	An unusual cause of pulmonary infiltrates mimicking pulmonary edema: metastatic calcifications. ⁶²	Suen CH...Hon YW	36204407	2022
11	Repurposing drugs for highly prevalent diseases: pentoxifylline, an old drug and a new opportunity for diabetic kidney disease. ⁶²	Donate-Correa J...Navarro-Gonzalez JF	36381364	2022
12	Pro- and anti-fibrotic effects of vascular endothelial growth factor in chronic kidney diseases. ⁶²	Miao C...Du Y	35618410	2022
13	A case series of perioperative anaphylaxis to cefazolin during kidney transplant and review of literature. ⁶²	Salehin S...Mujtaba MA	36126905	2022
14	Evaluation of screening with urine dipsticks and renal ultrasonography for 3-year-olds in Chiba City over 30 years. ⁶²	Matsumura C...Yamaguchi J	36056980	2022
15	Abnormal cerebral micro-structures in end-stage renal disease patients related to mild cognitive impairment. ⁶²	Zheng J...Shi H	36379097	2022
16	Polymorphisms in glucose homeostasis genes are associated with cardiovascular and renal parameters in patients with diabetic nephropathy. ⁶²	Mota-Zamorano S...Gervasini G	36314849	2022
17	Trends in the incidence of renal replacement therapy by type of primary kidney disease in Japan, 2006-2020. ⁶²	Wakasugi M...Narita I	36461735	2022
18	Peritoneal dialysis in the era of COVID-19: experience of a Tunisian center. ⁶²	Badrouchi S...Abderrahim E	35913609	2022
19	Addition of glomerular lesion severity improves the value of anemia status for the prediction of renal outcomes in Chinese patients with type 2 diabetes. ⁶²	Zhao L...Liu F	35188068	2022
20	Utilization of HCV viremic donors in kidney transplantation: a chance or a threat? ⁶²	Czarnecka P...Durlik M	35260039	2022
21	Fetal therapy of LUTO (lower urinary tract obstruction) - a follow-up observational study. ⁶²	Keil C...Weber S	34652254	2022
22	Drug-induced liver injury by glecaprevir/pibrentasvir treatment for chronic hepatitis C infection: a systematic review and meta-analysis. ⁶²	Hung HY...Chen CY	34969349	2022
23	Negative anti-phospholipase A2 receptor antibody status at three months predicts remission in primary membranous nephropathy. ⁶²	Stefan G...Mircescu G	35172682	2022
24	Endoscopic sleeve gastroplasty: results from a single surgical bariatric centre. ⁶²	Polese L...Foletto M	36168089	2022
25	Twelve-Month Outcomes From the Japanese Post-Market Surveillance Study of the Viabahn Endoprosthesis as Treatment for Symptomatic Peripheral Arterial Disease in the Superficial Femoral Arteries. ⁶²	Iida O...Ichihashi S	34905961	2022
26	Development and internal validation of machine learning algorithms for end-stage renal disease risk prediction model of people with type 2 diabetes mellitus and diabetic kidney disease. ⁶²	Zou Y...Liu F	35373711	2022
27	Safe administration of temozolomide in end-stage renal disease patients. ⁶²	Hundal J...Vredenburg J	36457294	2022
28	Association between cause of kidney failure and fracture incidence in a national US dialysis population cohort study. ⁶²	Ziolkowski S...O'Shaughnessy MM	36381373	2022
29	[Renal manifestations in connective tissue diseases]. ⁶²	Herrnstadt GR...Melderis S	36348023	2022
30	Risk factors for recurrent IgA nephropathy after renal transplantation: A meta-analysis. ⁶²	Bai J...Guo Q	36475355	2022
31	Clinicopathological characteristics and risk factors in elderly patients with biopsy-proven IgA nephropathy. ⁶²	Tan J...Qin W	35766236	2022
32	Plasma porphyrins among end stage renal disease patients and cutaneous symptoms- is there still an association? ⁶²	Goldman S...Levi A	36281443	2022
33	The problem of pulmonary arterial hypertension in end-stage renal disease: can peritoneal dialysis be the solution. ⁶²	Alhwiesh AK...Skhiri S	36471276	2022
34	Evaluation of standard versus reduced dose apixaban for the treatment of venous thromboembolism in patients with severe renal disease (ESRD-VTE). ⁶²	Knueppel P...Pon T	36306678	2022
35	DXA-derived advanced hip analysis and the trabecular bone score in end-stage kidney disease secondary to type 1 diabetes. ⁶²	Aleksova J...Elder GJ	36315195	2022
36	End-stage renal disease: incidence and prediction by coronary heart disease, and educational level. Follow-up from diagnosis of childhood-onset type 1 diabetes throughout Norway 1973-2017. ⁶²	Saeed M...Skrivarhaug T	35398254	2022
37	Anti-glomerular basement membrane disease: Treatment outcome of cyclophosphamide vs. rituximab induction therapy regimen. ⁶²	Jaryal A...Vikrant S	36282172	2022
38	Impact of the Kidney Transplantation Moratorium in France Because of the COVID-19 Pandemic: A Cohort-based Study. ⁶²	Bonnemains V...Foucher Y	36195001	2022
39	Lentiviral vector mediated gene therapy for type I Dent disease ameliorates Dent disease-like phenotypes for three months in ClC-5 null mice. ⁶²	Yadav MK...Lu B	36284768	2022
40	Caring for parents with end-stage renal disease: What do adult children face and how do they cope? ⁶²	Sousa H...Figueiredo D	34897863	2022
41	Patients with sickle cell disease who develop end-stage kidney disease continue to experience poor survival - A 19-year United States Renal Data System study. ⁶²	Winer JC...Zahr RS	36191963	2022
42	Sickle Cell Disease and the Kidney: Filters Gone Awry. ⁶²	Lebensburger JD...Derebail VK	36400541	2022
43	Cardiovascular outcomes of transradial versus transfemoral percutaneous coronary intervention in End-Stage renal Disease: A Regression-Based comparison. ⁶²	Sattar Y...Chadi Alraies M	36051245	2022
44	Supporting dialysis policy for end stage renal disease (ESRD) in Indonesia: an updated cost-effectiveness model. ⁶²	Putri S...Afiatin	36474238	2022
45	Changes in serum pigment epithelium-derived factor levels after kidney transplantation in patients with end-stage renal disease. ⁶²	Szentimrei R...Paragh G	36217673	2022
46	End-stage renal disease incidence in a cohort of US firefighters from San Francisco, Chicago, and Philadelphia. ⁶²	Pinkerton LE...Daniels RD	36268894	2022
47	The prognostic value of speckle tracking echocardiography in patients with end stage renal disease on dialysis. ⁶²	Kakiouzi V...Tsioufis C	36445672	2022
48	Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and End-Stage Renal Disease: Lessons Learned. ⁶²	Benz AP...Eikelboom JW	36469596	2022
49	Delivery of Radioiodine Ablation in a Patient with End-Stage Renal Disease. ⁶²	Bussey AT...Richardson M	36398301	2022
50	Feasibility of a break-in period of less than 24 hours for urgent start peritoneal dialysis: a multicenter study. ⁶²	Wen X...Cui W	35272577	2022

Sources

Genes for End Stage Renal Disease

Genes related to End Stage Renal Disease (0 elite genes):

(show top 50) (show all 56)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	ACE	Angiotensin I Converting Enzyme	Protein Coding	27.36	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
2	EPO	Erythropoietin	Protein Coding	26.51	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
3	APOL1	Apolipoprotein L1	Protein Coding	25.43	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
4	MYH9	Myosin Heavy Chain 9	Protein Coding	24.52	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
5	CFH	Complement Factor H	Protein Coding	23.81	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
6	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	23.55	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
7	CD2AP	CD2 Associated Protein	Protein Coding	23.54	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
8	ACTN4	Actinin Alpha 4	Protein Coding	23.08	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
9	RNLS	Renalase, FAD Dependent Amine Oxidase	Protein Coding	22.92	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Expressions (show sections)
10	PON1	Paraoxonase 1	Protein Coding	22.91	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
11	THBD	Thrombomodulin	Protein Coding	22.86	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
12	INVS	Inversin	Protein Coding	22.76	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
13	PVT1	Pvt1 Oncogene	RNA Gene	22.45	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Summaries (show sections)
14	IL1RN	Interleukin 1 Receptor Antagonist	Protein Coding	22.18	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
15	NEK8	NIMA Related Kinase 8	Protein Coding	22.16	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
16	SOD2	Superoxide Dismutase 2	Protein Coding	22	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
17	SLC9A5	Solute Carrier Family 9 Member A5	Protein Coding	20.88	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Summaries (show sections)
18	HFE	Homeostatic Iron Regulator	Protein Coding	20.85	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
19	BDKRB2	Bradykinin Receptor B2	Protein Coding	20.47	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Functions (show sections)
20	BDKRB1	Bradykinin Receptor B1	Protein Coding	20.23	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Functions (show sections)
21	COL4A3	Collagen Type IV Alpha 3 Chain	Protein Coding	15.58	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
22	COL4A5	Collagen Type IV Alpha 5 Chain	Protein Coding	15.25	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
23	PKD1	Polycystin 1, Transient Receptor Potential Channel Interacting	Protein Coding	15.22	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
24	COL4A4	Collagen Type IV Alpha 4 Chain	Protein Coding	15.15	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
25	PKD2	Polycystin 2, Transient Receptor Potential Cation Channel	Protein Coding	14.99	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
26	AGXT	Alanine--Glyoxylate Aminotransferase	Protein Coding	14.76	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
27	CFHR5	Complement Factor H Related 5	Protein Coding	14.68	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
28	INF2	Inverted Formin 2	Protein Coding	14.64	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
29	PAX2	Paired Box 2	Protein Coding	14.58	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
30	C3	Complement C3	Protein Coding	14.56	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
31	TRPC6	Transient Receptor Potential Cation Channel Subfamily C Member 6	Protein Coding	14.52	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
32	CD46	CD46 Molecule	Protein Coding	14.35	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
33	CFHR1	Complement Factor H Related 1	Protein Coding	14.28	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
34	GRHPR	Glyoxylate And Hydroxypyruvate Reductase	Protein Coding	14.08	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
35	CFHR3	Complement Factor H Related 3	Protein Coding	14.01	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
36	NPHP4	Nephrocystin 4	Protein Coding	14	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
37	DGKE	Diacylglycerol Kinase Epsilon	Protein Coding	13.97	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
38	CFI	Complement Factor I	Protein Coding	13.96	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
39	NPHP3	Nephrocystin 3	Protein Coding	13.96	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
40	CFB	Complement Factor B	Protein Coding	13.92	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
41	GANAB	Glucosidase II Alpha Subunit	Protein Coding	13.79	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
42	LMX1B	LIM Homeobox Transcription Factor 1 Beta	Protein Coding	13.46	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
43	DNAJB11	DnaJ Heat Shock Protein Family (Hsp40) Member B11	Protein Coding	13.3	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
44	TTC21B	Tetratricopeptide Repeat Domain 21B	Protein Coding	13.3	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
45	WDR19	WD Repeat Domain 19	Protein Coding	12.99	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
46	GLIS2	GLIS Family Zinc Finger 2	Protein Coding	12.77	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
47	HSPG2	Heparan Sulfate Proteoglycan 2	Protein Coding	12.7	DISEASES inferred ¹⁴ GeneCards inferred via : Proteins (show sections)
48	MYO1E	Myosin IE	Protein Coding	12.57	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
49	DZIP1L	DAZ Interacting Zinc Finger Protein 1 Like	Protein Coding	12.5	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
50	ROBO2	Roundabout Guidance Receptor 2	Protein Coding	12.25	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)

Sources

Variations for End Stage Renal Disease

Sources

Expression for End Stage Renal Disease

Search GEO for disease gene expression data for End Stage Renal Disease.

Sources

Pathways for End Stage Renal Disease

Pathways related to End Stage Renal Disease according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	ACE Inhibitor Pathway, Pharmacodynamics ⁶⁰ Show member pathways ACE inhibitor pathway ⁷⁴ Agents Acting on the Renin-Angiotensin System Pathway, Pharmacodynamics ⁶⁰ Conversion of angiotensinogen to angiotensin II ⁷⁴ Defective SERPING1 causes hereditary angioedema ⁶⁶ Downregulation of ACE2 by SARS-CoV-2 spike protein ⁷⁴ Kinin-Kallikrein pathway ⁷⁴ Non-classical role of vitamin D ⁷⁴ RAS and bradykinin pathways in COVID-19 ⁷⁴ Renin-angiotensin-aldosterone system (RAAS) ⁷⁴ SARS-CoV-2 and ACE2 receptor: molecular mechanisms ⁷⁴	11.39	BDKRB2 BDKRB1 ACE
2	Primary focal segmental glomerulosclerosis (FSGS) ⁷⁴	10.99	MYH9 CD2AP ACTN4
3	Nephrotic syndrome ⁷⁴	10.61	MYH9 CD2AP APOL1 ACTN4

Sources

GO Terms for End Stage Renal Disease

Cellular components related to End Stage Renal Disease according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular space	GO:0005615	9.66	VEGFA THBD RNLS PON1 IL1RN HFE
2	ciliary inversin compartment	GO:0097543	9.13	NEK8 INVS

Biological processes related to End Stage Renal Disease according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	response to nutrient levels	GO:0031667	9.72	SOD2 PON1 ACE
2	response to salt stress	GO:0009651	9.67	EPO BDKRB2
3	response to hypoxia	GO:0001666	9.65	VEGFA SOD2 EPO ACTN4 ACE
4	positive regulation of peptidyl-tyrosine autophosphorylation	GO:1900086	9.46	VEGFA ACE
5	negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stress	GO:1902219	9.43	EPO BDKRB2
6	response to lipopolysaccharide	GO:0032496	9.32	THBD SOD2 EPO BDKRB1 ACE